# Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

> **NCT06398158** · — · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 35 (estimated)

## Conditions studied

- Neuromyelitis Optica

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT06398158
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398158, "Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06398158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*